Loading…

Identification and characterization of a cross-neutralization epitope of Enterovirus 71

Abstract Enterovirus 71 (EV71) infections in children manifest as exanthema and are most commonly known as hand-foot-and-mouth disease (HFMD). Because it can cause severe neurological complications like poliomyelitis, EV71 has now emerged as an important neurotropic virus in Asia. EV71 virus has bee...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2011-06, Vol.29 (26), p.4362-4372
Main Authors: Liu, Chia-Chyi, Chou, Ai-Hsiang, Lien, Shu-Pei, Lin, Hsiao-Yu, Liu, Shih-Jen, Chang, Jui-Yuan, Guo, Meng-Shin, Chow, Yen-Hung, Yang, Wun-Syue, Chang, Kate Hsuen-Wen, Sia, Charles, Chong, Pele
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c575t-29be298c9c2dc9ab120610fe3ecbb1d6c1b978d5ba54291a12371b8ecafc1e223
cites cdi_FETCH-LOGICAL-c575t-29be298c9c2dc9ab120610fe3ecbb1d6c1b978d5ba54291a12371b8ecafc1e223
container_end_page 4372
container_issue 26
container_start_page 4362
container_title Vaccine
container_volume 29
creator Liu, Chia-Chyi
Chou, Ai-Hsiang
Lien, Shu-Pei
Lin, Hsiao-Yu
Liu, Shih-Jen
Chang, Jui-Yuan
Guo, Meng-Shin
Chow, Yen-Hung
Yang, Wun-Syue
Chang, Kate Hsuen-Wen
Sia, Charles
Chong, Pele
description Abstract Enterovirus 71 (EV71) infections in children manifest as exanthema and are most commonly known as hand-foot-and-mouth disease (HFMD). Because it can cause severe neurological complications like poliomyelitis, EV71 has now emerged as an important neurotropic virus in Asia. EV71 virus has been shown to consist of 3 (A, B and C) genotypes and many subgenotypes. Although EV71 vaccine development has recently yielded promising preclinical results, yet the correlation between the content of antigen(s) in vaccine candidates and the level of protective antibody responses is not established. The neutralization epitope(s) of EV71 antigens could be used as the surrogate biomarker of vaccine potency. Using peptide ELISA, antisera generated from animals immunized with formalin-inactivated EV71 virion vaccine formulated in alum, EV71-specific neutralizing monoclonal antibody (nMAb) and a panel of 153 overlapping synthetic peptides covering the entire sequences of VP1, VP2 and VP3 of EV71, we screened for immunodominant linear neutralization epitope(s). Synthetic peptide VP2-28, corresponding to residues 136–150 of VP2, was found to bind to and inhibit the binding to EV71 of nMAb MAB979 that was found to have cross-neutralizing activity against different genotypes of EV71 virus. In addition, VP2-28 was found to be recognized only by neutralizing antisera generated from rabbits immunized with the formalin-inactivated whole EV71 virion vaccine but not by antisera from immunized mice and rats. During the epitope mapping, a murine EV71 genotype- and strain-specific linear neutralization epitope VP1–43 was identified within residues 211–220 of VP1. Furthermore, based on sequence alignment and structure prediction analysis using poliovirus as the template for molecular modeling, the VP1-43 and VP2-28 epitopes were shown to run in parallel within 0.1 nm and form a rim of the canyon at the junction site of VP1 and VP2 in the viral capsid. In mouse, rat and rabbit immunogenicity studies, a dose-dependent relationship between the number of VP2-28 epitope units measured by a quantitative assay in vaccine preparations and the magnitude of neutralizing titers was demonstrated. VP2-28 has amino acid sequences that are highly conserved among EV71 genotypes, is not affected by formalin-treatment and long-term storage. Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines.
doi_str_mv 10.1016/j.vaccine.2011.04.010
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_874186814</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X11005202</els_id><sourcerecordid>3477138431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c575t-29be298c9c2dc9ab120610fe3ecbb1d6c1b978d5ba54291a12371b8ecafc1e223</originalsourceid><addsrcrecordid>eNqNkk-LFDEQxYMo7rj6EZQGEU89VqWT_nNRZNnVhQUPKnoL6epqzNiTHpPugfXTm96ZdWEvegokv3rk1XtCPEdYI2D5ZrPeWyLneS0BcQ1qDQgPxArrqsilxvqhWIEsVa4Qvp-IJzFuAEAX2DwWJxJ10lDFSny77NhPrndkJzf6zPouox82WJo4uN-Hy7HPbEZhjDH3PE_BDrcvvHPTuOOFOPdpYty7MMeswqfiUW-HyM-O56n4enH-5exjfvXpw-XZ-6ucdKWnXDYty6amhmRHjW1RQonQc8HUttiVhG1T1Z1urVayQYuyqLCtmWxPyFIWp-L1QXcXxl8zx8lsXSQeBut5nKOpK4V1WaP6DxK0lk1VJfLlPXIzzsEnGwZLrBuVNBdKH6ibxQTuzS64rQ3XBsEsEZmNOUZklogMKJMiSnMvjupzu-Xu79RtJgl4dQRsJDv0wXpy8Y5TsgSJi_V3B47TfveOg4nk2BN3LjBNphvdP7_y9p4CDc6nKgw_-ZrjnWsTpQHzeenTUifE1CQJsvgDoiXGZw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1618947417</pqid></control><display><type>article</type><title>Identification and characterization of a cross-neutralization epitope of Enterovirus 71</title><source>Elsevier</source><creator>Liu, Chia-Chyi ; Chou, Ai-Hsiang ; Lien, Shu-Pei ; Lin, Hsiao-Yu ; Liu, Shih-Jen ; Chang, Jui-Yuan ; Guo, Meng-Shin ; Chow, Yen-Hung ; Yang, Wun-Syue ; Chang, Kate Hsuen-Wen ; Sia, Charles ; Chong, Pele</creator><creatorcontrib>Liu, Chia-Chyi ; Chou, Ai-Hsiang ; Lien, Shu-Pei ; Lin, Hsiao-Yu ; Liu, Shih-Jen ; Chang, Jui-Yuan ; Guo, Meng-Shin ; Chow, Yen-Hung ; Yang, Wun-Syue ; Chang, Kate Hsuen-Wen ; Sia, Charles ; Chong, Pele</creatorcontrib><description>Abstract Enterovirus 71 (EV71) infections in children manifest as exanthema and are most commonly known as hand-foot-and-mouth disease (HFMD). Because it can cause severe neurological complications like poliomyelitis, EV71 has now emerged as an important neurotropic virus in Asia. EV71 virus has been shown to consist of 3 (A, B and C) genotypes and many subgenotypes. Although EV71 vaccine development has recently yielded promising preclinical results, yet the correlation between the content of antigen(s) in vaccine candidates and the level of protective antibody responses is not established. The neutralization epitope(s) of EV71 antigens could be used as the surrogate biomarker of vaccine potency. Using peptide ELISA, antisera generated from animals immunized with formalin-inactivated EV71 virion vaccine formulated in alum, EV71-specific neutralizing monoclonal antibody (nMAb) and a panel of 153 overlapping synthetic peptides covering the entire sequences of VP1, VP2 and VP3 of EV71, we screened for immunodominant linear neutralization epitope(s). Synthetic peptide VP2-28, corresponding to residues 136–150 of VP2, was found to bind to and inhibit the binding to EV71 of nMAb MAB979 that was found to have cross-neutralizing activity against different genotypes of EV71 virus. In addition, VP2-28 was found to be recognized only by neutralizing antisera generated from rabbits immunized with the formalin-inactivated whole EV71 virion vaccine but not by antisera from immunized mice and rats. During the epitope mapping, a murine EV71 genotype- and strain-specific linear neutralization epitope VP1–43 was identified within residues 211–220 of VP1. Furthermore, based on sequence alignment and structure prediction analysis using poliovirus as the template for molecular modeling, the VP1-43 and VP2-28 epitopes were shown to run in parallel within 0.1 nm and form a rim of the canyon at the junction site of VP1 and VP2 in the viral capsid. In mouse, rat and rabbit immunogenicity studies, a dose-dependent relationship between the number of VP2-28 epitope units measured by a quantitative assay in vaccine preparations and the magnitude of neutralizing titers was demonstrated. VP2-28 has amino acid sequences that are highly conserved among EV71 genotypes, is not affected by formalin-treatment and long-term storage. Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2011.04.010</identifier><identifier>PMID: 21501643</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Amino Acid Sequence ; Amino acids ; Animals ; Antibodies, Viral - blood ; Antibodies, Viral - immunology ; Applied microbiology ; Biological and medical sciences ; Canyons ; Capsid Proteins - chemistry ; Capsid Proteins - immunology ; Cell Line, Tumor ; Cercopithecus aethiops ; Cross Reactions ; Cross-genotype neutralizing antibody ; Enterovirus ; Enterovirus - classification ; Enterovirus - genetics ; Enterovirus - immunology ; Enterovirus Infections - prevention &amp; control ; Enterovirus Infections - virology ; Epitope Mapping ; EV71 vaccine ; Fundamental and applied biological sciences. Psychology ; Genotypes ; Hand-foot-and-mouth disease (HFMD) ; Immunization ; Immunodominant Epitopes - chemistry ; Immunodominant Epitopes - immunology ; Immunogenicity ; Inactivated whole virion vaccine ; Infections ; Mice ; Microbiology ; Miscellaneous ; Models, Molecular ; Molecular Sequence Data ; Neutralization ; Neutralization Tests ; Peptides ; Peptides - chemical synthesis ; Peptides - immunology ; Poliovirus ; Poliovirus - chemistry ; Poliovirus - genetics ; Potency assay development ; Proteins ; Rabbits ; Rats ; Studies ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Inactivated - immunology ; Vero Cells ; Viral Vaccines - immunology ; Virology</subject><ispartof>Vaccine, 2011-06, Vol.29 (26), p.4362-4372</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 10, 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c575t-29be298c9c2dc9ab120610fe3ecbb1d6c1b978d5ba54291a12371b8ecafc1e223</citedby><cites>FETCH-LOGICAL-c575t-29be298c9c2dc9ab120610fe3ecbb1d6c1b978d5ba54291a12371b8ecafc1e223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24260212$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21501643$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Chia-Chyi</creatorcontrib><creatorcontrib>Chou, Ai-Hsiang</creatorcontrib><creatorcontrib>Lien, Shu-Pei</creatorcontrib><creatorcontrib>Lin, Hsiao-Yu</creatorcontrib><creatorcontrib>Liu, Shih-Jen</creatorcontrib><creatorcontrib>Chang, Jui-Yuan</creatorcontrib><creatorcontrib>Guo, Meng-Shin</creatorcontrib><creatorcontrib>Chow, Yen-Hung</creatorcontrib><creatorcontrib>Yang, Wun-Syue</creatorcontrib><creatorcontrib>Chang, Kate Hsuen-Wen</creatorcontrib><creatorcontrib>Sia, Charles</creatorcontrib><creatorcontrib>Chong, Pele</creatorcontrib><title>Identification and characterization of a cross-neutralization epitope of Enterovirus 71</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Enterovirus 71 (EV71) infections in children manifest as exanthema and are most commonly known as hand-foot-and-mouth disease (HFMD). Because it can cause severe neurological complications like poliomyelitis, EV71 has now emerged as an important neurotropic virus in Asia. EV71 virus has been shown to consist of 3 (A, B and C) genotypes and many subgenotypes. Although EV71 vaccine development has recently yielded promising preclinical results, yet the correlation between the content of antigen(s) in vaccine candidates and the level of protective antibody responses is not established. The neutralization epitope(s) of EV71 antigens could be used as the surrogate biomarker of vaccine potency. Using peptide ELISA, antisera generated from animals immunized with formalin-inactivated EV71 virion vaccine formulated in alum, EV71-specific neutralizing monoclonal antibody (nMAb) and a panel of 153 overlapping synthetic peptides covering the entire sequences of VP1, VP2 and VP3 of EV71, we screened for immunodominant linear neutralization epitope(s). Synthetic peptide VP2-28, corresponding to residues 136–150 of VP2, was found to bind to and inhibit the binding to EV71 of nMAb MAB979 that was found to have cross-neutralizing activity against different genotypes of EV71 virus. In addition, VP2-28 was found to be recognized only by neutralizing antisera generated from rabbits immunized with the formalin-inactivated whole EV71 virion vaccine but not by antisera from immunized mice and rats. During the epitope mapping, a murine EV71 genotype- and strain-specific linear neutralization epitope VP1–43 was identified within residues 211–220 of VP1. Furthermore, based on sequence alignment and structure prediction analysis using poliovirus as the template for molecular modeling, the VP1-43 and VP2-28 epitopes were shown to run in parallel within 0.1 nm and form a rim of the canyon at the junction site of VP1 and VP2 in the viral capsid. In mouse, rat and rabbit immunogenicity studies, a dose-dependent relationship between the number of VP2-28 epitope units measured by a quantitative assay in vaccine preparations and the magnitude of neutralizing titers was demonstrated. VP2-28 has amino acid sequences that are highly conserved among EV71 genotypes, is not affected by formalin-treatment and long-term storage. Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines.</description><subject>Allergy and Immunology</subject><subject>Amino Acid Sequence</subject><subject>Amino acids</subject><subject>Animals</subject><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - immunology</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Canyons</subject><subject>Capsid Proteins - chemistry</subject><subject>Capsid Proteins - immunology</subject><subject>Cell Line, Tumor</subject><subject>Cercopithecus aethiops</subject><subject>Cross Reactions</subject><subject>Cross-genotype neutralizing antibody</subject><subject>Enterovirus</subject><subject>Enterovirus - classification</subject><subject>Enterovirus - genetics</subject><subject>Enterovirus - immunology</subject><subject>Enterovirus Infections - prevention &amp; control</subject><subject>Enterovirus Infections - virology</subject><subject>Epitope Mapping</subject><subject>EV71 vaccine</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genotypes</subject><subject>Hand-foot-and-mouth disease (HFMD)</subject><subject>Immunization</subject><subject>Immunodominant Epitopes - chemistry</subject><subject>Immunodominant Epitopes - immunology</subject><subject>Immunogenicity</subject><subject>Inactivated whole virion vaccine</subject><subject>Infections</subject><subject>Mice</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Models, Molecular</subject><subject>Molecular Sequence Data</subject><subject>Neutralization</subject><subject>Neutralization Tests</subject><subject>Peptides</subject><subject>Peptides - chemical synthesis</subject><subject>Peptides - immunology</subject><subject>Poliovirus</subject><subject>Poliovirus - chemistry</subject><subject>Poliovirus - genetics</subject><subject>Potency assay development</subject><subject>Proteins</subject><subject>Rabbits</subject><subject>Rats</subject><subject>Studies</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Vero Cells</subject><subject>Viral Vaccines - immunology</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqNkk-LFDEQxYMo7rj6EZQGEU89VqWT_nNRZNnVhQUPKnoL6epqzNiTHpPugfXTm96ZdWEvegokv3rk1XtCPEdYI2D5ZrPeWyLneS0BcQ1qDQgPxArrqsilxvqhWIEsVa4Qvp-IJzFuAEAX2DwWJxJ10lDFSny77NhPrndkJzf6zPouox82WJo4uN-Hy7HPbEZhjDH3PE_BDrcvvHPTuOOFOPdpYty7MMeswqfiUW-HyM-O56n4enH-5exjfvXpw-XZ-6ucdKWnXDYty6amhmRHjW1RQonQc8HUttiVhG1T1Z1urVayQYuyqLCtmWxPyFIWp-L1QXcXxl8zx8lsXSQeBut5nKOpK4V1WaP6DxK0lk1VJfLlPXIzzsEnGwZLrBuVNBdKH6ibxQTuzS64rQ3XBsEsEZmNOUZklogMKJMiSnMvjupzu-Xu79RtJgl4dQRsJDv0wXpy8Y5TsgSJi_V3B47TfveOg4nk2BN3LjBNphvdP7_y9p4CDc6nKgw_-ZrjnWsTpQHzeenTUifE1CQJsvgDoiXGZw</recordid><startdate>20110610</startdate><enddate>20110610</enddate><creator>Liu, Chia-Chyi</creator><creator>Chou, Ai-Hsiang</creator><creator>Lien, Shu-Pei</creator><creator>Lin, Hsiao-Yu</creator><creator>Liu, Shih-Jen</creator><creator>Chang, Jui-Yuan</creator><creator>Guo, Meng-Shin</creator><creator>Chow, Yen-Hung</creator><creator>Yang, Wun-Syue</creator><creator>Chang, Kate Hsuen-Wen</creator><creator>Sia, Charles</creator><creator>Chong, Pele</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20110610</creationdate><title>Identification and characterization of a cross-neutralization epitope of Enterovirus 71</title><author>Liu, Chia-Chyi ; Chou, Ai-Hsiang ; Lien, Shu-Pei ; Lin, Hsiao-Yu ; Liu, Shih-Jen ; Chang, Jui-Yuan ; Guo, Meng-Shin ; Chow, Yen-Hung ; Yang, Wun-Syue ; Chang, Kate Hsuen-Wen ; Sia, Charles ; Chong, Pele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c575t-29be298c9c2dc9ab120610fe3ecbb1d6c1b978d5ba54291a12371b8ecafc1e223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Allergy and Immunology</topic><topic>Amino Acid Sequence</topic><topic>Amino acids</topic><topic>Animals</topic><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - immunology</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Canyons</topic><topic>Capsid Proteins - chemistry</topic><topic>Capsid Proteins - immunology</topic><topic>Cell Line, Tumor</topic><topic>Cercopithecus aethiops</topic><topic>Cross Reactions</topic><topic>Cross-genotype neutralizing antibody</topic><topic>Enterovirus</topic><topic>Enterovirus - classification</topic><topic>Enterovirus - genetics</topic><topic>Enterovirus - immunology</topic><topic>Enterovirus Infections - prevention &amp; control</topic><topic>Enterovirus Infections - virology</topic><topic>Epitope Mapping</topic><topic>EV71 vaccine</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genotypes</topic><topic>Hand-foot-and-mouth disease (HFMD)</topic><topic>Immunization</topic><topic>Immunodominant Epitopes - chemistry</topic><topic>Immunodominant Epitopes - immunology</topic><topic>Immunogenicity</topic><topic>Inactivated whole virion vaccine</topic><topic>Infections</topic><topic>Mice</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Models, Molecular</topic><topic>Molecular Sequence Data</topic><topic>Neutralization</topic><topic>Neutralization Tests</topic><topic>Peptides</topic><topic>Peptides - chemical synthesis</topic><topic>Peptides - immunology</topic><topic>Poliovirus</topic><topic>Poliovirus - chemistry</topic><topic>Poliovirus - genetics</topic><topic>Potency assay development</topic><topic>Proteins</topic><topic>Rabbits</topic><topic>Rats</topic><topic>Studies</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Vero Cells</topic><topic>Viral Vaccines - immunology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Chia-Chyi</creatorcontrib><creatorcontrib>Chou, Ai-Hsiang</creatorcontrib><creatorcontrib>Lien, Shu-Pei</creatorcontrib><creatorcontrib>Lin, Hsiao-Yu</creatorcontrib><creatorcontrib>Liu, Shih-Jen</creatorcontrib><creatorcontrib>Chang, Jui-Yuan</creatorcontrib><creatorcontrib>Guo, Meng-Shin</creatorcontrib><creatorcontrib>Chow, Yen-Hung</creatorcontrib><creatorcontrib>Yang, Wun-Syue</creatorcontrib><creatorcontrib>Chang, Kate Hsuen-Wen</creatorcontrib><creatorcontrib>Sia, Charles</creatorcontrib><creatorcontrib>Chong, Pele</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Family Health</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Chia-Chyi</au><au>Chou, Ai-Hsiang</au><au>Lien, Shu-Pei</au><au>Lin, Hsiao-Yu</au><au>Liu, Shih-Jen</au><au>Chang, Jui-Yuan</au><au>Guo, Meng-Shin</au><au>Chow, Yen-Hung</au><au>Yang, Wun-Syue</au><au>Chang, Kate Hsuen-Wen</au><au>Sia, Charles</au><au>Chong, Pele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification and characterization of a cross-neutralization epitope of Enterovirus 71</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2011-06-10</date><risdate>2011</risdate><volume>29</volume><issue>26</issue><spage>4362</spage><epage>4372</epage><pages>4362-4372</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract Enterovirus 71 (EV71) infections in children manifest as exanthema and are most commonly known as hand-foot-and-mouth disease (HFMD). Because it can cause severe neurological complications like poliomyelitis, EV71 has now emerged as an important neurotropic virus in Asia. EV71 virus has been shown to consist of 3 (A, B and C) genotypes and many subgenotypes. Although EV71 vaccine development has recently yielded promising preclinical results, yet the correlation between the content of antigen(s) in vaccine candidates and the level of protective antibody responses is not established. The neutralization epitope(s) of EV71 antigens could be used as the surrogate biomarker of vaccine potency. Using peptide ELISA, antisera generated from animals immunized with formalin-inactivated EV71 virion vaccine formulated in alum, EV71-specific neutralizing monoclonal antibody (nMAb) and a panel of 153 overlapping synthetic peptides covering the entire sequences of VP1, VP2 and VP3 of EV71, we screened for immunodominant linear neutralization epitope(s). Synthetic peptide VP2-28, corresponding to residues 136–150 of VP2, was found to bind to and inhibit the binding to EV71 of nMAb MAB979 that was found to have cross-neutralizing activity against different genotypes of EV71 virus. In addition, VP2-28 was found to be recognized only by neutralizing antisera generated from rabbits immunized with the formalin-inactivated whole EV71 virion vaccine but not by antisera from immunized mice and rats. During the epitope mapping, a murine EV71 genotype- and strain-specific linear neutralization epitope VP1–43 was identified within residues 211–220 of VP1. Furthermore, based on sequence alignment and structure prediction analysis using poliovirus as the template for molecular modeling, the VP1-43 and VP2-28 epitopes were shown to run in parallel within 0.1 nm and form a rim of the canyon at the junction site of VP1 and VP2 in the viral capsid. In mouse, rat and rabbit immunogenicity studies, a dose-dependent relationship between the number of VP2-28 epitope units measured by a quantitative assay in vaccine preparations and the magnitude of neutralizing titers was demonstrated. VP2-28 has amino acid sequences that are highly conserved among EV71 genotypes, is not affected by formalin-treatment and long-term storage. Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>21501643</pmid><doi>10.1016/j.vaccine.2011.04.010</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2011-06, Vol.29 (26), p.4362-4372
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_874186814
source Elsevier
subjects Allergy and Immunology
Amino Acid Sequence
Amino acids
Animals
Antibodies, Viral - blood
Antibodies, Viral - immunology
Applied microbiology
Biological and medical sciences
Canyons
Capsid Proteins - chemistry
Capsid Proteins - immunology
Cell Line, Tumor
Cercopithecus aethiops
Cross Reactions
Cross-genotype neutralizing antibody
Enterovirus
Enterovirus - classification
Enterovirus - genetics
Enterovirus - immunology
Enterovirus Infections - prevention & control
Enterovirus Infections - virology
Epitope Mapping
EV71 vaccine
Fundamental and applied biological sciences. Psychology
Genotypes
Hand-foot-and-mouth disease (HFMD)
Immunization
Immunodominant Epitopes - chemistry
Immunodominant Epitopes - immunology
Immunogenicity
Inactivated whole virion vaccine
Infections
Mice
Microbiology
Miscellaneous
Models, Molecular
Molecular Sequence Data
Neutralization
Neutralization Tests
Peptides
Peptides - chemical synthesis
Peptides - immunology
Poliovirus
Poliovirus - chemistry
Poliovirus - genetics
Potency assay development
Proteins
Rabbits
Rats
Studies
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Inactivated - immunology
Vero Cells
Viral Vaccines - immunology
Virology
title Identification and characterization of a cross-neutralization epitope of Enterovirus 71
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A25%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20and%20characterization%20of%20a%20cross-neutralization%20epitope%20of%20Enterovirus%2071&rft.jtitle=Vaccine&rft.au=Liu,%20Chia-Chyi&rft.date=2011-06-10&rft.volume=29&rft.issue=26&rft.spage=4362&rft.epage=4372&rft.pages=4362-4372&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2011.04.010&rft_dat=%3Cproquest_cross%3E3477138431%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c575t-29be298c9c2dc9ab120610fe3ecbb1d6c1b978d5ba54291a12371b8ecafc1e223%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1618947417&rft_id=info:pmid/21501643&rfr_iscdi=true